IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

PartnershipIDE892RG6505Positive

AI Analysis

Summary

IDEAYA Biosciences announced a clinical collaboration with Roche to evaluate its Phase 1 PRMT5 inhibitor IDE892 in combination with Roche's Phase 1 pan-RAS inhibitor RG6505 in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma.

Clinical Trial Data

Phase

Phase 1

Importance:6/10

Sentiment:

0.60

clinical collaborationcombination therapyPRMT5 inhibitorRAS inhibitorpancreatic cancer

Related Companies

$IDYA $RHHBY

Read the original article

Published by PR Newswire Clinical Trials on June 3, 2026 10:00 AM

Read Original